Universal Beteiligungs und Servicegesellschaft mbH Purchases 8,561 Shares of Becton, Dickinson and Company $BDX

Universal Beteiligungs und Servicegesellschaft mbH lifted its position in shares of Becton, Dickinson and Company (NYSE:BDX) by 4.0% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 222,786 shares of the medical instruments supplier’s stock after buying an additional 8,561 shares during the period. Universal Beteiligungs und Servicegesellschaft mbH’s holdings in Becton, Dickinson and Company were worth $41,699,000 at the end of the most recent quarter.

A number of other hedge funds have also modified their holdings of BDX. SOA Wealth Advisors LLC. boosted its position in Becton, Dickinson and Company by 256.8% during the 3rd quarter. SOA Wealth Advisors LLC. now owns 132 shares of the medical instruments supplier’s stock worth $25,000 after acquiring an additional 95 shares during the last quarter. Bell Investment Advisors Inc raised its holdings in shares of Becton, Dickinson and Company by 474.1% in the second quarter. Bell Investment Advisors Inc now owns 155 shares of the medical instruments supplier’s stock valued at $27,000 after purchasing an additional 128 shares during the last quarter. Grey Fox Wealth Advisors LLC bought a new stake in shares of Becton, Dickinson and Company in the third quarter worth $32,000. Bank of Jackson Hole Trust boosted its holdings in Becton, Dickinson and Company by 85.6% during the second quarter. Bank of Jackson Hole Trust now owns 206 shares of the medical instruments supplier’s stock worth $35,000 after purchasing an additional 95 shares during the last quarter. Finally, CVA Family Office LLC grew its position in Becton, Dickinson and Company by 79.5% in the second quarter. CVA Family Office LLC now owns 219 shares of the medical instruments supplier’s stock valued at $38,000 after purchasing an additional 97 shares in the last quarter. 86.97% of the stock is currently owned by institutional investors.

Becton, Dickinson and Company Trading Up 1.3%

Shares of NYSE:BDX opened at $206.04 on Thursday. Becton, Dickinson and Company has a 52-week low of $162.29 and a 52-week high of $251.99. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.64 and a current ratio of 1.11. The company has a market capitalization of $58.70 billion, a P/E ratio of 35.34, a price-to-earnings-growth ratio of 2.25 and a beta of 0.23. The company has a 50-day simple moving average of $196.96 and a 200 day simple moving average of $190.00.

Becton, Dickinson and Company (NYSE:BDX) last announced its quarterly earnings results on Thursday, November 6th. The medical instruments supplier reported $3.96 earnings per share for the quarter, topping analysts’ consensus estimates of $3.92 by $0.04. Becton, Dickinson and Company had a return on equity of 16.42% and a net margin of 7.68%.The firm had revenue of $5.89 billion for the quarter, compared to the consensus estimate of $5.91 billion. During the same quarter in the previous year, the business earned $3.81 earnings per share. The business’s revenue was up 8.3% compared to the same quarter last year. Becton, Dickinson and Company has set its FY 2026 guidance at 14.750-15.050 EPS. Sell-side analysts forecast that Becton, Dickinson and Company will post 14.43 earnings per share for the current year.

Becton, Dickinson and Company Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Wednesday, December 31st. Investors of record on Monday, December 8th were paid a $1.05 dividend. This is a boost from Becton, Dickinson and Company’s previous quarterly dividend of $1.04. The ex-dividend date was Monday, December 8th. This represents a $4.20 dividend on an annualized basis and a yield of 2.0%. Becton, Dickinson and Company’s dividend payout ratio (DPR) is currently 72.04%.

Analyst Ratings Changes

Several equities research analysts have commented on BDX shares. Piper Sandler cut their price target on shares of Becton, Dickinson and Company from $200.00 to $190.00 and set a “neutral” rating on the stock in a research report on Friday, November 7th. Morgan Stanley lifted their target price on Becton, Dickinson and Company from $197.00 to $210.00 and gave the company an “overweight” rating in a research report on Tuesday, December 2nd. Bank of America increased their price target on Becton, Dickinson and Company from $190.00 to $207.00 and gave the company a “neutral” rating in a research report on Monday, January 5th. Stifel Nicolaus raised their price target on Becton, Dickinson and Company from $210.00 to $215.00 and gave the company a “buy” rating in a research note on Wednesday, January 7th. Finally, Royal Bank Of Canada boosted their price target on Becton, Dickinson and Company from $202.00 to $210.00 and gave the stock a “sector perform” rating in a research report on Wednesday, December 17th. Four investment analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $207.64.

Insiders Place Their Bets

In other news, Director Bertram L. Scott sold 217 shares of the stock in a transaction dated Friday, November 7th. The shares were sold at an average price of $176.58, for a total value of $38,317.86. Following the transaction, the director directly owned 35,816 shares of the company’s stock, valued at $6,324,389.28. This represents a 0.60% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Michael David Garrison sold 1,610 shares of the firm’s stock in a transaction dated Thursday, January 15th. The stock was sold at an average price of $207.46, for a total transaction of $334,010.60. Following the sale, the executive vice president owned 12,095 shares of the company’s stock, valued at approximately $2,509,228.70. This represents a 11.75% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 2,662 shares of company stock worth $535,246. 0.40% of the stock is owned by company insiders.

About Becton, Dickinson and Company

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.